Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of inebilizumab in adults with generalized myasthenia gravis
jRCT2021210003Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of inebilizumab in myasthenia gravis (MG) (4 arms), sponsored by Amgen. Primary endpoint: Change from baseline in MG-ADL score at Week 26 (overall population). Started Aug 2021; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021210003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210003.